Pharmacy Focus : Episode 86

Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development

Commentary
Podcast

The Alzheimer disease treatment landscape is evolving with new FDA-approved antibody therapies and advancements in biomarker testing to enable earlier diagnosis and intervention.

Experts In The Episode

Pamela Spicer, neuroscience expert and therapy area Director, Citeline
Martin Tolar, MD, PhD, founder, president, CEO, Alzheon
Sharon Cohen, MD, FRCPC, medical director, site principal investigator, Toronto Memory Program

The Alzheimer disease treatment landscape is rapidly changing, with several new FDA-approved antibody therapies that target amyloid plaque and aim to slow disease progression. While the controversial approval of aducanumab faced challenges, newer drugs like lecanemab and donanemab have shown more promising results in clinical trials, demonstrating cognitive benefits. Additionally, the pipeline includes novel therapies targeting tau protein and other mechanisms. Advancements in biomarker development, including plasma and imaging tests, are also enabling earlier diagnosis and the potential for preventive treatments before the onset of clinical symptoms.

Recent Videos
Public Health Matters podcast logo
Virtual Reality for Pharmacy School | Image Credit: toxicoz - stock.adobe.com
Non Small Cell Lung Cancer (NSCLC) in the lung tissue – closeup view 3d illustration
Covid-19 Vaccine New Variant 2024-2025 | Image Credit: New Africa - stock.adobe.com
Pharmacy students, university, assignment, tiktok | Image Credit: .shock - stock.adobe.com
Pharmacy Students in Lab, TikTok | Image Credit: D Lahoud/peopleimages.com - adobe.stock.com
Medical students listening to a lecture in the lab - Image credit:  luckybusiness | stock.adobe.com
Social Media Learning Pharmacy Students | Image Credit: Rawpixel.com - stock.adobe.com
COVID-19 vaccine 2024-2025 Season | Image Credit: Alernon77 - stock.adobe.com
Doctor hands making a vaccination in the shoulder of patient